Csrwin, I don’t want to harp on but the fda went for the beagle issue, pre phase1...the TGA had phase 1 data to draw on, safety fine, and would’ve approved safety on this and straight into a phase 2...this was were the issue was.
They chose the fda cluster route.
If you reckon current management is doing a great job with the stock at 2cents for a mkt cap $22m, great.... I think it is a joke and the board has to act
Ann: Actinogen presents latest Xanamem data at AD Conference, page-45
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
0.001(4.17%) |
Mkt cap ! $73.62M | |||
| Open | High | Low | Value | Volume |
| 2.5¢ | 2.5¢ | 2.4¢ | $64.83K | 2.646M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 3924751 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 3226651 | 6 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |